Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon output. GLP-1 derivatives possess promising therapeutic results in treating type 2 di